Psychiatr. pro Praxi, 2005; 6: 285-288
PHARMACOTHERAPY AND PSYCHOTHERAPY OF ANXIETY DISORDERS
- Psychiatrické centrum Praha, 3. LF UK, Praha
The anxiety disorders are the most common mental disorders, yet many of these patients are still not treated effectively. The goal of treatment is not only to alleviate symptoms but also management of co-morbidities, improvement of quality of life, decrease of overall vulnerability and elimination of relapses. In patients with symptoms of mild to moderate intensity the first choice of evidence-based treatments should be psychotherapy. Cognitive behavioral therapy has been proven in controlled clinical trials as highly effective option in both short-term and long-term treatment. The aim of the treatment should always be achievement of a full remission; otherwise there is an increased risk of relapse. Drugs used to treat anxiety disorders should be chosen based on generally accepted guidelines and their adverse reactions and limitations should always be considered from person to person. Antidepressants are preferred to benzodiazepines, with selective serotonin reuptake inhibitors (SSRIs) as the first choice.
Keywords: Key words: anxiety disorders, pharmacotherapy, cognitive behavioral therapy.
Published: February 1, 2006 Show citation
References
- Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the tretment of generalized anxiety disorder: twenty-four-week placebo-controlled, dose-ranging study. B J Psychiatry 2001; 179: 15-22.
Go to original source... 
Go to PubMed... - Ansseau M, Dierick M, Buntinkx F, et al. High prevalence of mental disorders in primary care. J Affect Disord 2004; 78 (1): 49-55. Go to original source... Go to PubMed...
- Ballenger JC. Treatment of anxiety disorders to remission. J Clin Psychiatry 2001; 62 (suppl 12): 5-9.
- Barlow DH. Anxiety and its disorders: The nature and treatment of anxiety and panic. New York, Guilford 2002.
- Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine or their combination for panic disorder: a randomized controlled trial. JAMA 2000; 283:2529-2536. Go to original source... Go to PubMed...
- Beasley CM Jr, Koke SC, Nilsson ME, Gonzales JS. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: An updated meta-analysis. Clin Ther 2000; 22: 1319-1330. Go to original source... Go to PubMed...
- Biondi M, Picardi A. Increased probability of remaining in remission from panic disorder with agoraphobia after drug treatment in patients who received concurrent cognitive-behavioural therapy: A follow-up study. Psychoter Psychosom 2003; 72: 34-42. Go to original source... Go to PubMed...
- Bourin M, Lambert O. Pharmacotherapy of anxious disorders. Hom Psychopharmacol Clin Exp 2002; 17: 383-400. Go to original source... Go to PubMed...
- Deacon BJ, Abramowitz JS. Cognitive and behavioral treatments for anxiety disorders: A review of meta-analytic findings. J Clin Psychol 2004; 60: 429-441. Go to original source... Go to PubMed...
- Fisher PL, Durham RC. Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990. Psychol Med 1999; 29: 1425-1434. Go to original source... Go to PubMed...
- Golgen RN. Efficacy and tolerability of controlled-release paroxetine. Psychopharmacol Bull 2003; 37 (suppl 1): 176-186. Go to PubMed...
- Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlledrelease and immediate release paroxetine in the treatment of depression. J Clin Psychiatry 2002; 63: 577-584. Go to original source... Go to PubMed...
- Goodman WK. Escitalopram 10 mg/day is effective ion the treatment of generalized anxiety disorder. Program and abstracts of the 22nd Annual Conference of Anxiety disorders Association of America; March 21-24, 2002; Austin, Texas.
- Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry 2002; 63 (suppl 8): 17-23.
- Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19. Go to original source... Go to PubMed...
- Lepine JP. The epidemiology of anxiety disorders: Prevalence and societal costs. J Clin Psychiatry 2002; 63 (suppl 14): 4-8.
- Liebowitz MR, DeMartinis MA, Weihs K, et al. Efficacy of sertraline in severe generalized anxiety disorder: results of double-blind placebo-controlled study. J Clin Psychiatry 2003; 64: 785-792. Go to original source... Go to PubMed...
- Nagida DN, Hensley PL, Uhlenhuth EH. Review of the long-term effectiveness of cognitive behavioral therapy compared to medications in panic disorder. Depr Anxiety 2003; 17: 58-64. Go to original source... Go to PubMed...
- Otto MW, Hong JJ, Safren SA. Benzodiazepine discontinuation difficulties in panic disorder: conceptual model and outcome for cognitive-behavioral therapy. Curr Pharm Des 2002; 8: 75-80. Go to original source... Go to PubMed...
- Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release of venlafaxine in non-depressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157: 968-974. Go to original source... Go to PubMed...
- Rickels K, Rynn M. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 2002; 63 (suppl 14): 9-16.
- Sheehan DV, Mao CG. Paroxetine treatment of generalized anxiety disorder. Psychopharmacol Bull 2003; 37 (suppl 1): 64-75.